Valuation: Opus Genetics, Inc.

Market Cap 344M 301M 277M 258M 489M 32.78B 496M 3.32B 1.29B 16.11B 1.29B 1.26B 55.53B P/E 2026 *
-3.94x
P/E 2027 * -5.57x
Enterprise Value 344M 301M 277M 258M 489M 32.78B 496M 3.32B 1.29B 16.11B 1.29B 1.26B 55.53B EV / Sales 2026 *
22.7x
EV / Sales 2027 * 23.2x
Free-Float
88.94%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Opus Genetics, Inc.

1 day+1.20%
1 week+5.75%
Current month+2.92%
1 month+0.71%
3 months-7.03%
6 months+99.53%
Current year+110.45%
1 week 3.93
Extreme 3.93
4.38
1 month 3.62
Extreme 3.62
4.61
Current year 1.88
Extreme 1.88
5.81
1 year 0.98
Extreme 0.9815
5.81
3 years 0.65
Extreme 0.65
5.81
5 years 0.65
Extreme 0.65
6.6
10 years 0.65
Extreme 0.65
13.81
Manager TitleAgeSince
Chief Executive Officer 42 2023-10-31
Director of Finance/CFO 52 2025-09-01
President 60 2024-10-21
Director TitleAgeSince
Director/Board Member 77 2020-10-31
Chairman 56 2019-11-30
Director/Board Member 59 2020-10-31
Date Insider Type Main position Quantity % Market Cap.
05-17
The Foundation Fighting Blindness, Inc.
SellCompany -1,700,000 2.0886%
04-22Sell

Chairperson

7,470 0.0105%
04-22Sell

Head of Fin. Quality Assurance

1,641 0.0023%
Change 5-day change 1-year change 3-year change Capi.($)
+1.20%+5.75%+323.00%-1.17% 344M
+1.86%+0.48%+55.50%+163.08% 1,082B
+3.57%+3.29%+68.60%+61.03% 633B
+3.99%+3.05%+37.93%+93.37% 461B
+3.86%+1.64%+32.57%+24.89% 339B
-0.56%+0.96%+41.67%+39.35% 301B
-0.08%+1.30%+32.15%+44.48% 292B
-1.54%+2.81%-25.35%-39.61% 225B
+3.55%+4.41%+25.45%+66.28% 202B
+4.21%+2.65%+17.47%+71.11% 163B
Average +2.01%+5.76%+60.90%+52.28% 370.01B
Weighted average by Cap. +2.24%+5.69%+42.27%+83.13%

Financials

2026 *2027 *
Net sales 15.18M 13.27M 12.2M 11.37M 21.56M 1.45B 21.89M 146M 56.92M 710M 56.98M 55.76M 2.45B 14.83M 12.97M 11.92M 11.11M 21.07M 1.41B 21.38M 143M 55.61M 694M 55.67M 54.47M 2.39B
Net income -94.49M -82.6M -75.91M -70.76M -134M -9B -136M -911M -354M -4.42B -355M -347M -15.24B -67.77M -59.24M -54.45M -50.75M -96.26M -6.45B -97.72M -654M -254M -3.17B -254M -249M -10.93B
Net Debt - -
Logo Opus Genetics, Inc.
Opus Genetics, Inc. is a clinical-stage ophthalmic biotechnology company. The Company is engaged in developing gene therapies for the treatment of inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. The Company’s pipeline includes adeno-associated virus (AAV)-based investigational gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. Its pipeline also includes OPGx-BEST1 investigational gene therapy, designed to address mutations in the BEST1 gene, which is associated with retinal degeneration. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist being investigated to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 being investigated to slow the progression of non-proliferative diabetic retinopathy.
Employees
28
Date Price Change Volume
26-07-02 US$4.230 +1.20% 847,568
26-07-01 US$4.180 +1.70% 805,565
26-06-30 US$4.110 +1.23% 681,898
26-06-29 US$4.060 +1.50% 824,289
26-06-26 US$4.000 +7.53% 7,866,281
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
4.230USD
Average target price
10.56USD
Spread / Average Target
+149.54%

Quarterly revenue - Rate of surprise